Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
miscellaneous service companies in Europe:
sales of 5.27 billion Swedish Kronor [US$611.12 million]
of which 61%
of UNITED KINGDOM
(£551.40 million [US$757.42 million]
of which 54%
was Operating Genus PIC), and
GW Pharmaceuticals PLC
based in UNITED KINGDOM
(£407.91 million [US$560.32 million]
of which 100%
was Novel Therapeutics).
Galapagos NV reported sales of 530.26 million Euro (US$629.76 million)
December of 2020.
decrease of 40.8%
versus 2019, when the company's sales were 895.89 million Euro.